- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02445963
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
February 10, 2021 updated by: U.S. Army Medical Research and Development Command
A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity
This study is an open-label, dose-escalating Phase 1 investigation of S. flexneri 2a InvaplexAR vaccine.
A total of up to 40 subjects will receive one of four S. flexneri 2a InvaplexAR vaccine doses.
The vaccine will be administered intranasally (without adjuvant).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The vaccine will be administered on Days 0,14, and 28.
Volunteers (10 per group [8 minimum]) will receive the same dose at each vaccination dependent upon group assignment.
Groups will be divided according to the table below.
An interval no less than 1 week will separate the third dose of a group from the first dose of the next group (receiving an increased InvaplexAR dose).
Blood, stool, and saliva specimens will be collected at pre-specified intervals to examine systemic and mucosal vaccine antigen-specific immune responses.
Ocular tear samples will be collected in groups C and D. Vaccine safety will be actively monitored during vaccination and for 28 days following the third vaccine dose.
The decision to advance to the next dose level is based on the safety assessment (not immunogenicity).
A dose level with no occurrence of stopping criteria in the 7 days following the last vaccine dose will prompt moving to the next higher level.
All safety data will be summarized and reviewed with the research monitor prior to dose escalation.
In addition, a report of all safety data will be provided to the sponsor's safety office for informational purposes.
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- Walter Reed Army Institute of Research, Clinical Trials Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of enrollment.
- Completion and review of comprehension test (achieved > 70% accuracy).
- Signed informed consent document.
- Available for the required follow-up period and scheduled clinic visits.
- Women: Negative pregnancy test with understanding (through informed consent process) to not become pregnant nor to breastfeed during the study or within 3 months following last vaccination
Exclusion Criteria:
- Health problems (for example, chronic medical conditions such as psychiatric conditions, diabetes mellitus, hypertension, or any other conditions that might place the subjects at increased risk of adverse events)- study clinicians, in consultation with the PI, will use clinical judgment on a case-by-case basis to assess safety risks under this criterion. The PI will consult with the Research Monitor as appropriate.
- Clinically significant abnormalities on physical examination (chronic sinusitis or seasonal rhinitis) which compromise identification and interpretation of potential vaccine associated adverse effects.
- Use of immunosuppressive and/or immunomodulative drugs such as corticosteroids or chemotherapeutics that may influence antibody development.
- Immunosuppressive illnesses (including IgA deficiency defined by serum IgA below level of detection or <7mg/dL).
- Participation in research involving another investigational product (defined as receipt of an investigational product or exposure to an invasive investigational device) 30 days before planned date of first vaccination or anytime throughout the duration of the study until the last study safety visit.
- Positive blood test for HBsAG, HCV, HIV-1/HIV-2.
- Clinically significant abnormalities on basic laboratory screening.
- Presence of significant unexplained laboratory abnormalities that in the opinion of the PI may potentially confound the analysis of the study results.
- Current smoker or smoker in past 1 year ('smoker' defined as daily cigarette, cigar, or pipe use for a period of at least 1 month).
Research specific
- Structural abnormalities on sinus/nasal cavity examination.
- Rhinoplasty.
- Nasal polyps.
- Nasal ulcers.
- Deviated nasal septum. This question is being used to determine whether the volunteer has a clinically significant deviated septum that causes nasal obstruction (thereby causing difficulty breathing), interferes with normal sinus drainage, or obscures visualization of the posterior nasal cavity complicating examination and safety monitoring..
- Chronic sinusitis/rhinitis.
- Current or planned use of nasal topical corticosteroids and/or nasal spray medications in the 4 weeks prior to dosing or during the study vaccination period.
- Current or recent history (in the past 5 years) of reactive airway disease (asthma), chronic obstructive pulmonary disease, or chronic bronchitis.
- History of Bell's palsy.
- Chronic use (weekly or more often) of anti-diarrheal, anti-constipation, or antacid therapy (excluding use associated with spicy meals).
- Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on a regular basis; loose or liquid stools on other than an occasional basis.
- Personal or family history of inflammatory arthritis.
- Positive blood test for HLA-B27.
- History of allergy to any vaccine.
Prior Exposure to Shigella
- Serum IgG titer ≥ 2500 to Shigella flexneri 2a LPS.
- History of microbiologically confirmed Shigella infection in the past 3 years.
- Received previous experimental Shigella vaccine or live Shigella challenge.
- Travel to countries with symptoms of travelers' diarrhea where Shigella or other enteric infections are endemic (most of the developing world) within the past 6 months prior to dosing.
- Occupation involving handling of Shigella bacteria currently, or in the past 3 years.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 10 μg S. flexneri 2a Invaplex
10 subjects vaccinated on days 0, 14, 28
|
The investigational product is S. flexneri 2a InvaplexAR.
The product is composed of three individual components IpaB, IpaC, and LPS.
The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
|
Active Comparator: 50 μg S. flexneri 2a Invaplex
10 subjects vaccinated on days 0, 14, 28
|
The investigational product is S. flexneri 2a InvaplexAR.
The product is composed of three individual components IpaB, IpaC, and LPS.
The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
|
Active Comparator: 250 μg S. flexneri 2a Invaplex
10 subjects vaccinated on days 0, 14, 28
|
The investigational product is S. flexneri 2a InvaplexAR.
The product is composed of three individual components IpaB, IpaC, and LPS.
The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
|
Active Comparator: 500 μg S. flexneri 2a Invaplex
10 subjects vaccinated on days 0, 14, 28
|
The investigational product is S. flexneri 2a InvaplexAR.
The product is composed of three individual components IpaB, IpaC, and LPS.
The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Treatment Related Adverse Events
Time Frame: 166 days
|
Number of adverse events related to the vaccine for each arm
|
166 days
|
Antibody Titers Against IgG and IgA Immunizing Antigens
Time Frame: At screening and Days 0, 14, 28, 35, 42, and 56
|
Serum samples will be assayed for antibody titers against the immunizing antigens LPS, IpaB, IpaC, and S. flexneri 2a Invaplex at screening, and Days 0, 14, 28, 35, 42, and 56 for 36 subjects.
Previously established high-titer specimens will be included on each plate to track day to day interassay variation.
For each antigen, pre- and post-vaccination serum samples will be assayed side-by-side.
The antibody titer assigned to each sample will represent the geometric mean of duplicate tests performed on 2 different days.
Reciprocal endpoint titers < 5 will be assigned a value of 2.5 for computational purposes.
Seroconversion will be defined as a > 4-fold increase in endpoint titer between pre-and post-vaccination samples AND a post-vaccination reciprocal titer >10.
|
At screening and Days 0, 14, 28, 35, 42, and 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses
Time Frame: 56 Days
|
ASC responses were assessed using isolated peripheral blood mononuclear cells (PBMCs).
For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers.
The ASC responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites.
An ASC response was defined as > 10 ASCs above baseline.
|
56 Days
|
IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses
Time Frame: 56 Days
|
ALS responses were assessed using isolated peripheral blood mononuclear cells (PBMCs).
For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers.
The ALS responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites.
An ALS response was defined as a ≥ 4-fold increase over baseline ALS titers.
|
56 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Christopher Duplessis, MD, MPH, MS, Enteric Diseases Department Naval Medical Research Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2015
Primary Completion (Actual)
May 13, 2016
Study Completion (Actual)
May 13, 2016
Study Registration Dates
First Submitted
May 13, 2015
First Submitted That Met QC Criteria
May 14, 2015
First Posted (Estimate)
May 15, 2015
Study Record Updates
Last Update Posted (Actual)
February 12, 2021
Last Update Submitted That Met QC Criteria
February 10, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-15-19
- A-18716 (Other Identifier: Walter Reed Army Institute of Research)
- NMRC.2015.0003 (Other Identifier: Naval Medical Research Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shigellosis
-
GlaxoSmithKlineRecruiting
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdRecruiting
-
PATHUnited States Department of Defense; Johns Hopkins University Center for Immunization...Completed
-
LimmaTech Biologics AGKEMRI-Wellcome Trust Collaborative Research Program; Kenya Medical Research...Completed
-
PATHCompleted
-
International Centre for Diarrhoeal Disease Research...Karolinska Institutet; Swedish International Development Cooperation Agency...Completed
-
University of OxfordJohns Hopkins University; Walter Reed Army Institute of Research (WRAIR); KEMRI-Wellcome... and other collaboratorsNot yet recruiting
-
Intralytix, Inc.University of Maryland, BaltimoreRecruiting
-
International Centre for Diarrhoeal Disease Research...GlaxoSmithKline; University of WashingtonRecruiting
-
GSK Vaccines Institute For Global Health S.r.l.Completed
Clinical Trials on Shigella flexneri 2a InvaplexAR
-
U.S. Army Medical Research and Development CommandU.S. Army Office of the Surgeon GeneralCompletedShigellosisUnited States
-
U.S. Army Medical Research and Development CommandCompleted
-
University of Maryland, BaltimorePATHTerminated
-
PATHWithdrawnShigella Sonnei DysenteriesUnited States
-
University of Maryland, BaltimorePATHCompleted
-
University of Maryland, BaltimorePATHTerminated
-
Eunice Kennedy Shriver National Institute of Child...The Chaim Sheba Medical Center; Schneider Children's Medical Center, IsraelCompleted
-
University of Maryland, BaltimoreActive, not recruiting
-
PATHUnited States Department of Defense; Johns Hopkins University Center for Immunization...Completed
-
Peter MacCallum Cancer Centre, AustraliaCompletedCancer | Covid19 | Respiratory Viral InfectionAustralia